Filter By Category
Archives
Share on -
AVACINCAPTAD PEGOL
Generic Name: AVACINCAPTAD PEGOL
ABSTRACT -
Avacincaptad pegol is a PEGylated RNA aptamer that binds complement component C5 and is used as an intravitreal complement inhibitor for geographic atrophy secondary to age-related macular degeneration where approved. It is an oligonucleotide/PEG conjugate, not a conventional small molecule, so the representation above is an aptamer-PEG schematic.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- Use only according to the approved local product label and institutional administration procedures.
- Infusion or injection settings must have monitoring and emergency support as required for the product class.
- Do not administer outside authorized indications or specialist supervision.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Eye pain, conjunctival hemorrhage, vitreous floaters, or increased intraocular pressure
- Blurred vision or transient visual disturbance after intravitreal injection
- Ocular inflammation, retinal tear, or retinal detachment may occur rarely
- Endophthalmitis is rare but serious after intravitreal injection
- Hypersensitivity reactions are possible
ALLERGIC REACTIONS -
Hypersensitivity to Avacincaptad pegol or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Avacincaptad pegol should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Avacincaptad pegol may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Other intravitreal medicines should be scheduled according to ophthalmology guidance.
- Anticoagulants or antiplatelet medicines may increase ocular bleeding risk.
- Recent ocular infection or inflammation may require postponement.
- Patients should inform eye-care providers about all medicines and ocular procedures.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Administer only by clinicians trained in intravitreal injection technique.
- Evaluate for active ocular or periocular infection before treatment.
- Monitor vision changes and intraocular pressure as clinically indicated.
- Patients should seek urgent care for eye pain, worsening redness, photophobia, or sudden vision loss.
WARNINGS –
- Intravitreal injection can cause endophthalmitis, retinal detachment, and increased intraocular pressure.
- Do not administer during active ocular or periocular infection.
- Benefits and risks should be reviewed for each treated eye.
- Keep out of reach of children.
Share on -
. Developed by